CalAmp Launches End-To-End Supply Chain Visibility Solution for Cold Chain
CalAmp's new sensor for cold-chain applications provides visibility for shipping vaccines.
CalAmp, a California-based connected intelligence company, announced in an April 21, 2021 press release that it has launched the SC1302 single-use smart tracking device that can monitor temperatures as low as -20 °C. The smart device provides granular visibility for the safe and efficient transport of COVID-19 vaccines and other high-value shipments.
The sensor integrates with CalAmp's SC iOn Supply Chain Visibility software solution for real-time, end-to-end monitoring of shipments through a web interface. Third-party logistics providers and others can monitor environmental conditions of environmentally-sensitive shipments throughout the supply chain. Sensor data can alternatively be integrated into other software solutions and managed through the CalAmp Telematic Cloud platform.
CalAmp's wireless sensors and other reusable and single-use devices track and collect data, such as temperature, light, shock, vibration, and location throughout the shipment journey. During flight or if out of cellular coverage, the sensors will continue to log the environmental data and automatically synchronize with CalAmp's fixed and mobile hubs once back in range.
Complete logging of data helps document chain of custody in compliance with good distribution practice requirements.
The sensors and disposable devices use GPS tracking to provide near real-time delivery estimates, current location, and progress reports. Alerts notify users if the cargo deviates from the planned route and can indicate if a shipment is moving or stalled. The system integrates with electronic data interchange or enterprise resource planning systems to facilitate information sharing.
Source: CalAmp
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
